Determination of rapamycin in whole blood by HPLC

Therapeutic Drug Monitoring

Volumn 19, Issue 1, 1997, Pages 112-116

  Svensson, J O ^a   Brattstrom C ^a   Sawe J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cyclosporine; Rapamycin; Sirolimus; Tacrolimus

Indexed keywords

MACROLIDE; RAPAMYCIN;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POLYENES; SIROLIMUS;

EID: 0031410316     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199702000-00022     Document Type: Article

References (17)

1. Calne R, Lim S, Samaan A, Collier SJ, Pollars SG, White DJG. Rapamycin for immunosuppression of organ allografting. Lancet 1989;2:227.
2. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989;17:609-10.
3. Stepkowski SM, Chen H, Daloze P, Kahan BD. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney and small bowel transplantation in the rat. Transplantation 1991;51: 22-6.
4. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK 506 selectively inhibits expression of early T-cell activation genes. J Immunol 1989;143:718-26.
5. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T-C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991;51:232-9.
6. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK 506 and cyclosporine. Nature 1991;352:803-7.
7. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Siga NH. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK 506 and rapamycin. J Immunol 1990;144: 251-8.
8. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan BD. Low-dose rapamycin potentiates the effect of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993;55:947-9.
9. Honchank N, Fryer I, Yatschoff R. Pharmacokinetics of rapamycin: single dose studies in the rabbit. Ther Drug Monit 1992;14: 475-8.
10. Napoli KL, Kahan BD. High performance liquid chromatography of rapamycin. Clin Chem 1991;37:294-5.
11. Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamcyin. Transplantation 1993;56:1202-6.
12. Fryer J, Yatscoff RW, Pascoe EA, Thliveris J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation 1993;55:340-5.
13. Yatscoff RW, Faraci C, Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Ther Drug Monit 1992;14:138-41.
14. Hushes P, Musser J, Conklin M, Russo R. The isolation, synthesis and characterization of an isomeric form of rapamycin. Tetrahedron Lett 1992;33:4739-42.
15. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992;20:186-91.
16. Sattler M, Guengerich FP, Chul-Ho Yun, Christians U, Sewing K-FR. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
17. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43: 630-5.